<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221451</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15299</org_study_id>
    <secondary_id>2019-002375-34</secondary_id>
    <secondary_id>U1111-1197-7905</secondary_id>
    <nct_id>NCT04221451</nct_id>
  </id_info>
  <brief_title>A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2</brief_title>
  <acronym>AMETHIST</acronym>
  <official_title>A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the&#xD;
      efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over&#xD;
      a 104-week period&#xD;
&#xD;
      Secondary population (participants with juvenile/adolescent late-onset GM2 gangliosidosis,&#xD;
      GM1 gangliosidosis, saposin C deficiency, sialidosis type 1 or juvenile/adult&#xD;
      galactosialidosis): To assess PD response (plasma and CSF GL-1 biomarker and disease specific&#xD;
      biomarkers) of venglustat when administered once daily over a 104-week period&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Primary population:&#xD;
&#xD;
        -  To assess the effect of venglustat on selected performance test and scale over a&#xD;
           104-week period&#xD;
&#xD;
        -  To determine the safety and tolerability of venglustat when administered orally once&#xD;
           daily over a 104-week period&#xD;
&#xD;
        -  To assess the pharmacokinetics (PK) of venglustat in plasma and cerebrospinal fluid&#xD;
           (CSF)&#xD;
&#xD;
      Secondary population:&#xD;
&#xD;
        -  To assess the effect of venglustat on selected performance tests and scale over a&#xD;
           104-week period&#xD;
&#xD;
        -  To determine the safety and tolerability of venglustat when administered once daily over&#xD;
           a 104-week period&#xD;
&#xD;
        -  To assess the PK of venglustat in plasma and CSF&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration is up to approximately 119 weeks, including a 60-day screening period, a&#xD;
      104-week treatment period, and a 6-week post-treatment safety observation period.&#xD;
&#xD;
      Participants who complete the Week 110 assessments of the current study will be given the&#xD;
      option to enroll in a long-term safety (LTS) follow-up study to assess safety and&#xD;
      tolerability of venglustat.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">January 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cerebrospinal fluid (CSF) GM2 biomarker</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Percent change in CSF GM2 biomarker from baseline to Week 104 in primary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the 9-hole pegboard test (9-HPT)</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Annualized rate of change in the 9-HPT from baseline to Week 104 in primary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pharmacodynamic (PD) response in plasma: GL-1, GM1 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 biomarker and pathway specific biomarker GM1 for GM1 gangliosidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in plasma: GL-1, GM2 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 and GM2 for GM2 gangliosidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in plasma: GL-1, GM2, GM3 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 and GM2, GM3 for sialidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in plasma: GL-1, GM1, GM3 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 and GM1, GM3 for galactosialidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in plasma: GL-1 biomarker</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 for saposin C deficiency in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in CSF: GL-1, GM1 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 biomarker and pathway specific biomarker GM1 for GM1 gangliosidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in CSF: GL-1, GM2 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 and GM2 for GM2 gangliosidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in CSF: GL-1, GM2, GM3 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 and GM2, GM3 for sialidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in CSF: GL-1, GM1, GM3 biomarkers</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 and GM1, GM3 for galactosialidosis in secondary population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PD response in CSF: GL-1 biomarker</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Concentration of GL-1 for saposin C deficiency in secondary population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/tolerability: Adverse events</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameters in plasma: Cmax</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Maximum venglustat concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters in plasma: tmax</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Time to maximum venglustat concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters in plasma: AUC0-24h</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Concentration versus time curve calculated using the trapezoidal method from time 0 to 24 hours (AUC0-24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters in CSF: Cmax</measure>
    <time_frame>Week 104</time_frame>
    <description>Maximum venglustat concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters in CSF: tmax</measure>
    <time_frame>Week 104</time_frame>
    <description>Time to maximum venglustat concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters in CSF: AUC0-24h</measure>
    <time_frame>Week 104</time_frame>
    <description>Concentration versus time curve calculated using the trapezoidal method from time 0 to 24 hours (AUC0-24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 25-foot walk test (FWT)</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Change in timed 25-FWT from baseline to Week 104 (in patients able to walk at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the neurological examination of the Friedreich's Ataxia Rating Scale (FARS)</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Change in the neurological examination of the FARS score from baseline to Week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 9-hole peg test (9-HPT)</measure>
    <time_frame>From baseline to Week 104</time_frame>
    <description>Annualized rate of change in the 9-HPT from baseline to Week 104 in secondary population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Tay-Sachs Disease Sandhoff Disease</condition>
  <arm_group>
    <arm_group_label>GZ402671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary population: participant will receive venglustat dose 1 once daily during 104 weeks.&#xD;
Secondary population: participant will receive venglustat at various doses once daily during 104 weeks (open label period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Primary population: participants will receive placebo once daily during 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venglustat GZ402671</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>GZ402671</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Primary population and adult secondary population: age ≥ 18 years&#xD;
&#xD;
          -  Juvenile/adolescent secondary population: 2 ≥ age &lt; 18 years with weight ≥ 10 kg&#xD;
&#xD;
          -  Participants with a diagnosis of late onset GM2 gangliosidosis (Tay-Sachs disease and&#xD;
             Sandhoff disease) caused by genetic β-hexosaminidase deficiency resulting from&#xD;
             mutations in the HEXA or HEXB genes (primary population only); a secondary population&#xD;
             will enroll patients with diagnosis of juvenile/adolescent GM2 gangliosidosis, GM1&#xD;
             gangliosidosis, saposin C deficiency, sialidosis type 1 or juvenile adult&#xD;
             galactosialidosis&#xD;
&#xD;
          -  For primary population, the participant has the ability to perform the 9-HPT at the&#xD;
             screening visit in &lt; = 240 seconds for the 2 consecutive trials of the dominant hand&#xD;
             and the 2 consecutive trials of the nondominant hand.&#xD;
&#xD;
          -  Participants with a history of seizures well controlled by medication other than&#xD;
             strong or moderate inducer or inhibitor of CYP3A4&#xD;
&#xD;
          -  Participant is cooperative, able to ingest oral medication, willing to travel to a&#xD;
             study site (if applicable), and able to comply with all aspects of the study,&#xD;
             including all assessments, according to the Investigator's judgement&#xD;
&#xD;
          -  Signed written informed assent/consent&#xD;
&#xD;
          -  Contraception for sexually active male participants or female patient; not pregnant or&#xD;
             breastfeeding; no sperm donating for male participant&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Participant has clinical features of Tay-Sachs or Sandhoff disease, not caused by&#xD;
             β-hexosaminidase deficiency resulting from mutations in the HEXA or HEXB genes and/or&#xD;
             is without clinical features&#xD;
&#xD;
          -  For primary population and participants with juvenile/adolescent late onset GM2&#xD;
             gangliosidosis and GM1 gangliosidosis, the participant cannot understand and perform&#xD;
             all age-appropriate study assessments with the exception of 25FWT and PROs.&#xD;
&#xD;
          -  Relevant medical disorders that would compromise his/her safety&#xD;
&#xD;
          -  Documented diagnosis of hepatitis B, C, human immunodeficiency virus 1 or 2&#xD;
&#xD;
          -  World Health Organization (WHO) grade &gt;= 2 cortical cataract or a grade &gt;= 2 posterior&#xD;
             subcapsular cataract; patients with nuclear cataracts will be accepted&#xD;
&#xD;
          -  Participant who requires invasive ventilatory support&#xD;
&#xD;
          -  Current treatment by anticoagulants, cataractogenic medications or any medications&#xD;
             that may worsen the vision of patient with cataract&#xD;
&#xD;
          -  Previous treatment with substrate reduction therapy (SRT) within 3 months prior to&#xD;
             study enrollment, strong or moderate inducers or inhibitors of CYP3A4 within 14 days&#xD;
             or 5 half-lives prior to enrollment. This also includes the consumption of grapefruit,&#xD;
             grapefruit juice or grapefruit products within 72hrs prior to starting investigational&#xD;
             medicinal product (IMP) administration.&#xD;
&#xD;
          -  Current participation in another study&#xD;
&#xD;
          -  Use of investigational medicinal product (IMP) within 3 months or 5 half-lives,&#xD;
             whichever is longer, before study enrollment (for N-acetyl-leucine, within 5&#xD;
             half-lives before study enrollment).&#xD;
&#xD;
          -  Liver enzymes (alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) or&#xD;
             total bilirubin &gt; 2 x the upper limite of normal (ULN) at the time of screening unless&#xD;
             the participant has the diagnosis of Gilbert syndrome and maintains a level of&#xD;
             bilirubin &lt; 5 mg/dl and direct bilirubin &lt; 20% (1 mg/dl) of total bilirubin level&#xD;
&#xD;
          -  Renal insufficiency is defined by estimated glomerular filtration rate (eGFR) &lt; 30&#xD;
             mL/min/1.73m2 at the screening visit&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ataxia Center and HD Center of Excellence, 300 UCLA Med Plaza, Suite B200 - Investigational site number 8400004</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <phone>310-206-8153</phone>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Genetics - Investigational site number 8400006</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Laney</last_name>
    </contact>
    <investigator>
      <last_name>William Wilcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH National Human Genome Research Institute - 10 Center Dr - Bldg. 10 CRC3-2551 MSC 1205 - Investigational site number 8400005</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ashton</last_name>
      <phone>240-274-8168</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Tifft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Charles River Plaza 175 Cambridge St. Ste 340 - Investigational site number 8400002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Kelly Clinical Research Coordinator</last_name>
      <phone>617-724-1330</phone>
    </contact>
    <investigator>
      <last_name>Florian Eichler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone - 550 First Avenue-Investigational site number 8400001</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral Pilar, Buenos Aires_Unidad de Investigación Clínica_investigational site number 0320002</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1629AHJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hernan.amartino@gmail.com</last_name>
      <phone>54 230 438 7649</phone>
      <email>mcremona@austral.edu.ar</email>
    </contact>
    <investigator>
      <last_name>Hernán Amartino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria Reina Fabiola Córdoba_investigational site number 0320001</name>
      <address>
        <city>Córdoba</city>
        <zip>X5004FHP</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romina Miodowsky</last_name>
      <phone>54 351 414 2121</phone>
      <email>romimiodowsky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Norberto Guelbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKH Wien_Universitätsklinik für Innere Medizin III Klinische Abteilung für Endokrinologie &amp; Stoffwechsel Währinger Gürtel 18-20_investigational site number 0400001</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Potuzak</last_name>
      <phone>43 140400 43370</phone>
      <email>vera.potuzak@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Alexandra Kautzky-Willer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre _investigational site number 0760001</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Pedrini</last_name>
      <phone>55 51 3359-6341</phone>
      <email>dianebpedrini@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roberto Giugliani, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice V Praze Metabolicke centrum U Nemocnice 2_investigational site number 2030001</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Pencová</last_name>
      <email>metabolickecentrum@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Pavel Jesina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Centre Hospitalier la Pitié Salpetrière, Service de Neurologie, 47-83 Boulevard De l'Hôpital_Investigational site number 2500001</name>
      <address>
        <city>Paris</city>
        <zip>Cedex 13-75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine LEFORT</last_name>
      <phone>01.42.16.57.62</phone>
      <email>carine.lefort@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yann NADJAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin Feulgenstraße 10-12_investigational site number 2760001</name>
      <address>
        <city>Gießen</city>
        <zip>35389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Hahn, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Akita Hospital 222-1 Nawashirosawa, Kamikitatesaruta_investigational site number 3920001</name>
      <address>
        <city>Akita-Shi</city>
        <zip>010-1495</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kana Inoue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tohoku Medical and Pharmaceutical University Hospital_investigation site number 3920002</name>
      <address>
        <city>Sendai</city>
        <zip>983-8512</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ichiro Nakashima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Lisboa Norte- Hospital Santa Maria Avenida Professor Egas Moniz_investigational site number 6200002</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tproencasantos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tiago Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center Of Neurology 80, Volokolamskoye shosse_investigational site number 6430001</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Ershova</last_name>
      <phone>79167486977</phone>
      <email>mvedoc@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Srgey Illarioshkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Maternoinfantil Sant Joan de Déu Paseo de Sant Joan de Déu, 2_investigational site number 7240001</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Llanos</last_name>
      <email>cllanosp@hsjdbcn.org</email>
    </contact>
    <investigator>
      <last_name>Maria Mar O'Callaghan Gordo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge. Feixa Llarga, S / N_investigational site number 7240004</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Fabra</last_name>
      <email>efabra@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Jordi Gascon Bayarri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago-CHUS. Travesia de Chopuana, s/n_investigational site number 7240002</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofía Gouveia</last_name>
      <email>sofia.bsg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Couce Pico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi Tip Fakultesi Emniyet Street Mevlana Blv Besevler Yenimahalle_investigational site number 7920001</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>fezgu@gazi.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Fatih Ezgu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust Addenbrookes Hospital Hills Road_investigational site number 8260001</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Morris</last_name>
      <phone>01223274634</phone>
      <email>liz.morris@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Timothy Cox, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust St Marys Hospital Manchester Royal Infirmary Oxford Road_investigational site number 8260003</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Seligman</last_name>
      <phone>0044161 701 8313</phone>
      <email>Ella.Seligman@mft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Hamilton</last_name>
      <phone>0044161 701 8313</phone>
      <email>Victoria.Hamilton@mft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust Salford Royal Hospital Stott Lane_investigational site number 8260002</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Meehan</last_name>
      <phone>00441612064851</phone>
      <email>Marie.Meehan@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ana Jovanovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tay-Sachs Disease</mesh_term>
    <mesh_term>Sandhoff Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

